Articles tagged "Kidney transplantation"

2017 American Transplant Congress
Does Choice of Induction Agent Affect Outcomes in Kidney Transplants from Deceased Donors with Acute Kidney Injury and Prolonged Cold Ischemia Time?
G. Dube, S. Mohan, M. Chiles.
Nephrology, Columbia University Medical Center, New York, NY
Kidneys with acute kidney injury (AKI) have a higher rate of DGF but similar outcomes to kidneys without AKI, although most data are with kidneys…
2017 American Transplant Congress
Differential Effect of Antibody Removal on ABO Blood Group Type Chain Specific Antibodies Over Time.
A. Bentall,¹ M. Jeyakanthan,² J. Pearcey,² B. Motyka,² C. Cairo,³ T. Lowary,³ J. Buriak,⁴ L. West,² S. Ball.¹
¹Department of Nephrology, University Hospital Birmingham, Birmingham, United Kingdom; ²Departs of Pediatrics, Surgery and Immunology, University of Alberta, Alberta Transplant Institute, Edmonton, Canada; ³Alberta Glycomics Centre, Univ of Alberta, Dept of Chemistry, Edmonton, Canada; ⁴Dept of Chemistry, National Institute of Nanotechnology, Edmonton, Canada
Introduction: The trisaccharide epitope defines A&B blood group antigens where antibody binds to subtype chains (I-VI), but only subtype II is expressed on cardiac vascular…
2017 American Transplant Congress
Worsening Rather Than Severe Acute Kidney Injury Affects Kidney Transplantation Outcomes.
M.-Y. Yu,¹ B. Yu,² Y. Kim,¹ S. Mi,³ J. Ha,³ J. Yang,³ Y. Kim,¹ H. Lee.¹
¹Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea; ²Internal Medicine, Soon Chun Hyang University Bucheon Hospital, Bucheon, Republic of Korea; ³Surgery, Seoul National University Hospital, Seoul, Republic of Korea
BackgroundThe growing evidence has suggested that deceased donor kidneys with acute kidney injury (AKI) may be a good solution to overcome organ shortage. Although previous…
2017 American Transplant Congress
Non-Directed Kidney Donor Candidate Referral, Care, and Attrition in an Online Portal.
R. Hays,¹ K. Schappe,¹ D. Kaufman,¹ D. Mandelbrot.²
¹Division of Transplant Surgery, University of Wisconsin Hospital and Clinics, Madison, WI; ²Division of Nephrology, Department of Medicine, University of Wisconsin Hospital and Clinics, Madison, WI
When non-directed live kidney donation (NDD) was first described in the early 2000s, a high rate of inquiry per actual donor was noted. Since then,…
2017 American Transplant Congress
M1 Macrophage-Induced Loss of KLF15 Promotes Chronic Podocyte Injury.
S. Han,^1,2 Y. Kim,¹ S. Lee,¹ H. Lee,^1,2 R.-H. Cha,² J. Lee,^1,2 J. Lee,² D. Kim,^1,2 Y. Kim,^1,2 S. Yang.^1,2
¹Internal Medicine, Seoul National University College of Medicine, Seoul, Korea; ²Kidney Research Institute, Seoul National University, Seoul, Korea
Background: Krüppel-like factor 15 (KLF15), kidney-enriched transcription factor, is known to participate in the differentiation of podocyte. However, the implication of KLF15 in chronic podocyte…
2017 American Transplant Congress
Do Perioperative Blood Transfusions Influence Kidney Transplant Outcomes in the Modern Era?
J. Lineen, J. Trac, Y. Li, O. Famure, J. Kim.
Multi-Organ Transplant Program, Toronto General Hospital, University Health Network, Toronto, ON, Canada
Background: Blood transfusions are a well-established risk factor for human leukocyte antigen sensitization in kidney transplant candidates. To date, relatively few studies have explored the…
2017 American Transplant Congress
A Comparative Study of Patient and Graft Qualities Between Abo-Compatible and -Incompatible Recipients More Than Ten Years After Kidney Transplantation.
H. Ishida, T. Shimizu, M. Okumi, K. Unagami, K. Omoto, K. Tanabe.
Urology, Tokyo Women's Medical University, Tokyo, Japan
Background. The long-term benefits of ABO-I kidney transplantation in terms of adverse events due to severe immunosuppression immediately before transplantation remain unclear.Patients and Methods. Between…
2017 American Transplant Congress
In Depth Characterization of Ex Vivo Expanded Polyclonal Regulatory T Cells Used in a Phase I Clinical Trial Following Kidney Transplantation.
J. Heinrichs,¹ J. Mathew,^1,2 I. Konieczna,¹ J. He,¹ X. Haung,¹ A. LeFever,¹ J. Leventhal.¹
¹Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL; ²Microbiology and Immunology, Northwestern University, Chicago, IL
Initial clinical trials have investigated the safety of regulatory T cells (Tregs) as a therapy during aberrant immune activation, like graft-versus-host disease (GVHD) following stem…
2017 American Transplant Congress
Tacrolimus Dose Variability, CYP3A5 Genotype, and Acute Rejection in African American and European American Kidney Transplant Recipients.
S. Seibert,¹ D. Schladt,² B. Wu,³ W. Guan,³ C. Dorr,^2,7 D. Berglund,¹ R. Remmel,⁴ A. Matas,⁵ R. Mannon,⁶ A. Israni,^2,7 W. Oetting,¹ P. Jacobson,¹ For the DeKAF Genomics Investigators.
¹Dept of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota (UMN), Mpls, MN; ²Chronic Disease Research Group, Minneapolis Medical Research Foundation, Mpls, MN; ³Division of Biostatistics, School of Public Health, UMN, Mpls, MN; ⁴Dept of Medicinal Chemistry, College of Pharmacy, UMN, Mpls, MN; ⁵Division of Transplantation, Dept of Surgery, School of Medicine, UMN, Mpls, MN; ⁶Dept of Nephrology, University of Alabama, Birmingham, AL; ⁷Dept of Nephrology, Hennepin County Medical Center, School of Medicine, UMN, Mpls, MN
Background: Poor immunosuppression with tacrolimus (TAC) after kidney transplantation contributes to the development of toxicity and loss of efficacy. We aimed to associate intra-patient TAC…
2017 American Transplant Congress
Optimization of Extended-Release Tacrolimus Dose with Mycophenolate Mofetile Based Immunosuppression in De Novo Kidney Transplant Recipients: 2 Years Outcome.
Y. Watarai,¹ S. Narumi,¹ M. Okada,¹ R. Kimura,¹ K. Hatazoe,¹ K. Futamura,¹ T. Yamamoto,¹ T. Hiramitsu,¹ M. Tsujita,¹ N. Goto,¹ T. Kobayashi.²
¹Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Aichi, Japan; ²Kidney Transplant Surgery, Aichi Medical University, Nagakute, Aichi, Japan
Purpose: Once-daily tacrolimus extended-release formulation (TACER) has been accepted in kidney transplantation, however its optimal dosing are not well determined. We have validated the institutional…